Salvat
FL - Miami
Biotechnology1 H-1B visas (FY2023)Focus: Small Molecules
Salvat is a life sciences company focused on Small Molecules.
OphthalmologyImmunology
Employees
201-500
Open Jobs
0
Products & Portfolio (2)
CETRAXAL
ciprofloxacin hydrochloride
LOE Approaching
OTIC · SOLUTION/DROPS
(see 12.4 Clinical Pharmacology, Microbiology).
acute otitis externa due to susceptible isolates of Pseudomonas aeruginosaStaphylococcus aureus
2009
30
OTOVEL
ciprofloxacin hydrochloride; fluocinolone acetonide
Peak
OTIC · SOLUTION/DROPS
2016
8
Pipeline & Clinical Trials
SVT-40776
Overactive Bladder (OAB)Clinical Trials (1)
NCT00507169SVT-40776 in Patients Suffering From Overactive Bladder Syndrome
Phase 2HC-SVT-1001
PseudoarthrosisClinical Trials (1)
NCT02483364A Clinical Trial to Assess the Effect of HC-SVT-1001 and HC-SVT-1002 in the Surgical Treatment of Atrophic Pseudarthrosis of Long Bones (Bonecure)
Phase 2DF289
Acute Otitis MediaClinical Trials (1)
NCT01404611Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients
Phase 3Clobetasol Propionate
Cataracts InfantileClinical Trials (1)
NCT05724446Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population
Phase 3SVT-15652
OtomycosisClinical Trials (1)
NCT03686397SVT-15652 Otic Solution for the Treatment of Otomycosis.
Phase 3DF277
Otic EczemaClinical Trials (1)
NCT01996748Clinical Study to Assess the Efficacy and Safety of DF277 Compared to Placebo in the Treatment of Otic Eczema
Phase 3Clobetasol propionate
CataractClinical Trials (1)
NCT04246801Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)
Phase 3DF289
Acute Otitis MediaClinical Trials (1)
NCT01395966Clinical Study to Assess the Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients
Phase 3SVT-15652
OtomycosisClinical Trials (1)
NCT03686384SVT-15652 Otic Solution for the Treatment of Otomycosis
Phase 3G238
OtomycosisClinical Trials (1)
NCT01993823Clinical Study to Assess the Efficacy and Safety of G238 Compared to Clotrimazole Otic Solution in the Treatment of Otomycosis
Phase 3DF289 plus DF277
Acute Otitis ExternaClinical Trials (1)
NCT03196973Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Acute Otitis Externa
Phase 3Clobetasol Propionate
CataractClinical Trials (1)
NCT04249076Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 2 approved products, 12 clinical trials
H-1B (2023): 1 approval
Portfolio Health
Peak1 (50%)
LOE Approaching1 (50%)
2 total products
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub